SAFETY AND EFFICACY OF COBI-BOOSTED ATAZANAVIR VERSUS RITONAVIR-BOOSTED ATAZANAVIR EACH ADMINISTERED WITH EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE IN HIV-1 INFECTED, ANTIRETROVIRAL TREATMENT-NAIVE ADULTS: